• Rosbiney Díaz-Ruiz, Lilia Aguilar-López, Arturo Vega-Ruiz, Oscar Garcés-Ruiz, Arnulfo Nava-Zavala, and Benjamín Rubio-Jurado.
• Servicio de Hematología, Unidad Médica de Alta Especialidad, HE, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Mexico.
• Gac Med Mex. 2015 Mar 1; 151 (2): 150-6.

IntroducctionAcute lymphoblastic leukemia (ALL) is a clonal disease characterized by a proliferation of immature cells. In immunophenotypic, cytogenetic and molecular studies, it is a heterogeneous disease with diverse manifestations and prognoses. The treatment is complex and is associated with complications during its course.Patients And MethodsA prospective study of cohort of patients with ALL. Subjects were recruited consecutively from April 2010 to November 2012 in the Specialties Hospital, /MSS.ResultsWe included 29 patients with ALL; of 16 females (55%) and 13 males (45%), 18 (64%) were treated with modified BFM, seven (25%) HiperCVAD, and three (11 %) others. In all, 70% achieved complete remission, and 8.5% partial responses. Induction mortality in five patients (17%). Consolidation mortality in three (13%). Relapse 33%, with a mean of eight months (5- 16 months), overall survival five months. At 26 months of follow-up, 13 patients (45%) maintained RC. Disease-free survival of 10 months and overall survival of 12 months was observed.ConclusionThe majority of patients, regardless of risk, reach complete remission. We found that the clinical and biological characteristics showed no significant differences related to the outcome. lmmunochemotherapy treatment may improve response.

12 keywords...

hide…